Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Safe cosmetics without animal testing? Contributions of the EU Project Sens-it-iv

Author:
  • Hans Ulrich Weltzien
  • Emanuela Corsini
  • Sue Gibbs
  • Malin Lindstedt
  • Carl Borrebaeck
  • Petra Budde
  • Peter Schulz-Knappe
  • Hermann-Josef Thierse
  • Stefan F. Martin
  • Erwin L. Roggen
Publishing year: 2009
Language: English
Pages: 41-48
Publication/Series: Journal für Verbraucherschütz und Lebensmittelsicherheit
Volume: 4
Issue: Suppl. 2
Document type: Journal article
Publisher: Birkhaüser

Abstract english

The 7th Ammendment to the Cosmetics Directive of the European Commission (Directive 76/768/EEC2) bans the marketing of cosmetics containing animal-tested ingredients since March 2009. Excepted are only tests for repeated dose toxicity, for which the animal ban will come into effect by 2013. One major concern for cosmetics, i.e. the risk of containing skin (contact) sensitizers, has in the past been addressed almost exclusively by animal testing. It is this problem attracting the central interest of the integrated research project Sens-it-iv (Novel Testing Strategies for in vitro Assessment of Allergens, http://www.sens-it-iv.eu ), funded by the EC within framework 6 since October 2005. Here, the 28 Sens-it-iv partners from 10 European States present the 5 most promising types of in vitro assays selected for further refinement. These are: (1) a human epidermal equivalent (EE) model to rank contact allergens according to their sensitizing potency, (2) identification of contact sensitizers, including pro-haptens, through intracellular production of IL-18 by the human keratinocyte cell line NCTC 2544, (3) determination of activation markers such as CD86, CD54 and most prominently CXCL8 (IL-8) on/in dendritic cell lines, (4) contact sensitizer-specific migration of MUTZ Langerhans cells towards the chemokine CXCL12, and (5) the allergen-specific activation and proliferation of na < ve human T cells. Ongoing genomic and proteomic experiments are in the process of identifying larger sensitizer-specific biological marker signatures to be integrated into the above assays. We hope to supply the European control agencies with a basis for further validation of in vitro assays by the end of 2010.

Keywords

  • Immunology in the medical area
  • Allergy
  • Contact
  • Sensitizer
  • In vitro
  • Alternative
  • Animal
  • Cosmetic

Other

Published
  • ISSN: 1661-5867
Carl Borrebaeck
E-mail: carl [dot] borrebaeck [at] immun [dot] lth [dot] se

Professor

Department of Immunotechnology

313k1

90

Director

Create Health

+46 46 222 96 13

313k1

90